A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China. Li W, Wan L. PLoS One 2023;18:e0286595.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Li W, Wan L. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China. PLoS One 2023;18:e0286595.
PMID: 37262075